TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
GRI Bio ( (GRI) ) has provided an announcement.
On August 13, 2025, GRI Bio, Inc. held its Annual Meeting of Stockholders virtually, where stockholders approved an amendment to the company’s 2018 Equity Incentive Plan, increasing the number of shares of common stock reserved for issuance by 400,000 shares. The meeting also included the election of Class II directors and the ratification of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions reflect GRI Bio’s strategic focus on enhancing its equity structure and ensuring strong governance as it looks towards future growth.
The most recent analyst rating on (GRI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on GRI Bio stock, see the GRI Stock Forecast page.
Spark’s Take on GRI Stock
According to Spark, TipRanks’ AI Analyst, GRI is a Neutral.
GRI Bio’s stock is constrained by weak financial performance, with ongoing losses and significant cash burn. Technical indicators and valuation metrics further suggest caution, as the stock trades in a downtrend with negative profitability. The strong equity position provides some support, but overall, the stock is risky with limited appeal under current conditions.
To see Spark’s full report on GRI stock, click here.
More about GRI Bio
Average Trading Volume: 251,080
Technical Sentiment Signal: Sell
Current Market Cap: $3.16M
For an in-depth examination of GRI stock, go to TipRanks’ Overview page.